Want to see NXGL full AI Analyst Report?
Earnings Data
Report Date
Aug 18, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.09Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Q1 2026
Earnings Call Date:May 15, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call emphasized a transformational acquisition (BioNX), strategic financing and partnership with Sequence LifeScience, strengthened leadership, a commercial product portfolio in ~500 hospitals, and pro forma projections to triple revenue to ~$35M and be accretive — all significant positives. Offsetting these are near‑term operational and liquidity pressures: Q1 revenue declined ~5.7% YoY, cash on hand fell to $1.8M, SG&A is elevated, and some legacy consumer products and key customer relationships have underperformed. Management reported early signs of recovery and initial BioNX sales beginning in Q2, but timing and execution risk remain notable.Company Guidance
Strategic Acquisition of BioNX Closed
Acquisition of BioNX closed in mid‑April; BioNX adds 6 commercial regenerative biomaterial products, positioning the company in a fast‑growing healthcare segment and providing an expanded commercial footprint.
Pro Forma Revenue Projection and Accretion
Management expects the transaction to approximately triple annual revenue to roughly $35 million on a pro forma basis and to be "immediately accretive to profitability" upon closing (company guidance/projection).
Material Financing and Strategic Partner
Company raised $13.8 million total (comprised of $8.8M received in cash and a $5.0M convertible note) to fund the acquisition and working capital. Sequence LifeScience led financing for BioNX with a $5.5M investment and has joined the company’s board, bringing manufacturing, product development, and distribution capabilities.
Commercial Footprint and Pipeline Investment
BioNX products are commercial stage and approved in approximately 500 U.S. hospitals. The company has 3 510(k) devices in development with approximately $4.6M of invested paid‑in capital targeted for commercialization (years cited in the call).
Management and Commercial Team Strengthening
Appointed Dave Hazard as VP of Sales for BioNX Surgical and added Ian Blackman as CFO; Sequence LifeScience executives Brian Keeser and Kevin Harris joined the board—strengthening commercial, scientific, and financial leadership.
Early Signs of Revenue Recovery and Initial BioNX Sales
Management reported Silly George sales 'normalize and recover' in April and expects to recognize roughly half of BioNX revenues in Q2 (first quarter did not include any BioNX revenue).
Positive Clinical/Study Result for Laser Hair Removal Product
Published study (sponsored by partner Innovative Optics) showed strong outcomes: ~90% reduction in plume, reduced pain as a secondary endpoint, and ~70% efficacy — a commercial opportunity via partner distribution relationships with laser manufacturers.
NXGL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NXGL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2026 | $0.54 | $0.51 | -5.90% |
Apr 21, 2026 | $0.74 | $0.65 | -13.04% |
Nov 11, 2025 | $2.28 | $2.02 | -11.40% |
Aug 12, 2025 | $2.71 | $2.40 | -11.44% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NexGel Inc (NXGL) report earnings?
NexGel Inc (NXGL) is schdueled to report earning on Aug 18, 2026, After Close (Confirmed).
What is NexGel Inc (NXGL) earnings time?
NexGel Inc (NXGL) earnings time is at Aug 18, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NXGL EPS forecast?
NXGL EPS forecast for the fiscal quarter 2026 (Q2) is -0.12.